Twist Bioscience Analyst Price Targets

Wall Street analyst price targets and consensus rating for Twist Bioscience (TWST).

Price Target Range — 11 Quarters

Analyst Consensus — 14 Analysts

10Buy

2Hold

2Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$90Upside to Avg. PT-53.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$107→$212
Sep 29, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$160→$190
Sep 18, 2026	BWS Financial	Hamed Khorsand	Maintained	Sell	$45
Sep 17, 2026	Leerink Partners	Puneet Souda	PT Raise	Outperform	$120→$160
Sep 9, 2026	BWS Financial	Hamed Khorsand	Initiate	Sell	$45
Sep 9, 2026	UBS	Doug Schenkel	Initiate	Neutral	$144
Aug 5, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$85→$115
Aug 4, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$113→$115
Jul 14, 2026	Canaccord Genuity	Kyle Mikson	PT Raise	Buy	$90→$120
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	Downgrade	Outperform→In-Line	$66→$102
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$60→$107
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$65→$95
Jun 15, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$68→$89
Jun 15, 2026	Canaccord Genuity	Kyle Mikson	Initiate	Buy	$90
Jun 11, 2026	Piper Sandler	David Westenberg	Initiate	Overweight	$85
May 5, 2026	Leerink Partners	Puneet Souda	Upgrade	Market Perform→Outperform	$70
May 5, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$55→$65
May 5, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$55→$60
May 5, 2026	Baird	Catherine Ramsey	PT Raise	Outperform	$50→$65
Apr 14, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$50→$55

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the price target from $107 to $212.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

Leerink Partners analyst Puneet Souda maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $160 to $190.

Benzinga Newsdesk

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Sell rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and raises the price target from $85 to $115.

Benzinga Newsdesk

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and raises the price target from $113 to $115.

Benzinga Newsdesk

Twist Bioscience Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

PRO
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

PRO
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

People Also Watch

People Also Watch

Twist Bioscience Corp

ニュース

パートナーシップ

ベンジンガ・グローバル

Twist Bioscience Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

PROLeerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

PROBWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

PROUBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

PROPiper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

PROBaird Maintains Outperform on Twist Bioscience, Raises Price Target to $115

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $212

PRO
Leerink Partners Maintains Outperform on Twist Bioscience, Raises Price Target to $190

PRO
BWS Financial Initiates Coverage On Twist Bioscience with Sell Rating, Announces Price Target of $45

PRO
UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

PRO
Piper Sandler Maintains Overweight on Twist Bioscience, Raises Price Target to $115

PRO
Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $115